Citations

Mayo Clinic

Showing 10 of 108522 citations.

miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Boufraqech, Myriem , Nilubol, Naris , Gara, Sudheer Kumar, Sadowski, Samira M. , Mehta, Amit, Davis, Sean , Dreiling, Jennifer L., Copland, John A. , Smallridge, Robert C., Quezado, Martha , Kebebew, Electron , Zhang, Lisa M. , He, Mei

Cancer Research | December 9, 2014 | Volume: 75 | Issue: 2 | Pages: 367-377

10.1158/0008-5472.can-14-2304 | PMID 25488748 Get It

Abstract Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, but its genetic drivers remain little understood. In this study, we report losses in expression of the miRNA miR30a, which is downregulated in ATC compared with differentiated thyroid cancer and normal tissue. miR30a downregulation was associated with advanced differentiated thyroid cancer and higher mortality. Mechanistically, we found miR30a decreased cellular invasion and migration, epithelial–mesenchymal transition marker levels, lysyl oxidase (LOX) expression, and metastatic capacity. LOX was identified as a direct target of miR30a that was overexpressed in ATC and associated with advanced differentiated thyroid cancer and higher mortality rate. Consistent with its role in other cancers, we found that LOX inhibited cell proliferation, cellular invasion, and migration and metastasis in vitro and in vivo. Together, our findings establish a critical functional role for miR30a downregulation in mediating LOX upregulation and thyroid cancer progression, with implications for LOX targeting as a rational therapeutic strategy in ATC. Cancer Res; 75(2); 367–77. ©2014 AACR.
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors
Hobday, Timothy J. , Qin, Rui , Reidy‐Lagunes, Diane , Moore, Malcolm J. , Kaubisch, Andreas , Shah, Manisha H. , Kindler, Hedy L. , Lenz, Heinz‐Josef , Erlichman, Charles , Shah, Manisha , Kindler, Hedy Lee, Chen, Helen, Strosberg, Jonathan , Chen, Helen

Journal of Clinical Oncology | December 9, 2014 | Volume: 33 | Issue: 14 | Pages: 1551-1556

10.1200/jco.2014.56.2082 | PMID 25488966 Get It

Purpose There are few effective therapies for pancreatic neuroendocrine tumors (PNETs). Recent placebo-controlled phase III trials of the mammalian target of rapamycin (mTOR) inhibitor everolimus and the vascular endothelial growth factor (VEGF)/platelet-derived growth factor receptor inhibitor sunitinib have noted improved progression-free survival (PFS). Preclinical studies have suggested enhanced antitumor effects with combined mTOR and VEGF pathway–targeted therapy. We conducted a clinical trial to evaluate combination therapy against these targets in PNETs. Patients and Methods We conducted a two-stage single-arm phase II trial of the mTOR inhibitor temsirolimus 25 mg intravenously (IV) once per week and the VEGF-A monoclonal antibody bevacizumab 10 mg/kg IV once every 2 weeks in patients with well or moderately differentiated PNETs and progressive disease by RECIST within 7 months of study entry. Coprimary end points were tumor response rate and 6-month PFS. Results A total of 58 patients were enrolled, and 56 patients were eligible for response assessment. Confirmed response rate (RR) was 41% (23 of 56 patients). PFS at 6 months was 79% (44 of 56). Median PFS was 13.2 months (95% CI, 11.2 to 16.6). Median overall survival was 34 months (95% CI, 27.1 to not reached). For evaluable patients, the most common grade 3 to 4 adverse events attributed to therapy were hypertension (21%), fatigue (16%), lymphopenia (14%), and hyperglycemia (14%). Conclusion The combination of temsirolimus and bevacizumab had substantial activity and reasonable tolerability in a multicenter phase II trial, with RR of 41%, well in excess of single targeted agents in patients with progressive PNETs. Six-month PFS was a notable 79% in a population of patients with disease progression by RECIST criteria within 7 months of study entry. On the basis of this trial, continued evaluation of combination mTOR and VEGF pathway inhibitors is warranted.
Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)
Loomba, Rohit , Sirlin, Claude B. , Ang, Brandon, Bettencourt, Ricki , Jain, Rashmi , Salotti, Joanie, Soaft, Linda, Hooker, Jonathan , Bhatt, Archana, Hernandez, Laura, Nguyen, Phirum, Noureddin, Mazen , Haufe, William, Hooker, Catherine A., Yin, Meng , Valasek, Mark A. , Brenner, David A. , Richards, Lisa , Kono, Yuko , Ehman, Richard L. , Lin, Grace , Sirlin, Claude B. , Loomba, Rohit , Yin, Meng

Hepatology | December 9, 2014 | Volume: 61 | Issue: 4 | Pages: 1239-1250

10.1002/hep.27647 | PMID 25482832 Get It

Ezetimibe inhibits intestinal cholesterol absorption and lowers low‐density lipoprotein cholesterol. Uncontrolled studies have suggested that it reduces liver fat as estimated by ultrasound in nonalcoholic steatohepatitis (NASH). Therefore, we aimed to examine the efficacy of ezetimibe versus placebo in reducing liver fat by the magnetic resonance imaging‐derived proton density‐fat fraction (MRI‐PDFF) and liver histology in patients with biopsy‐proven NASH. In this randomized, double‐blind, placebo‐controlled trial, 50 patients with biopsy‐proven NASH were randomized to either ezetimibe 10 mg orally daily or placebo for 24 weeks. The primary outcome was a change in liver fat as measured by MRI‐PDFF in colocalized regions of interest within each of the nine liver segments. Novel assessment by two‐dimensional and three‐dimensional magnetic resonance elastography was also performed. Ezetimibe was not significantly better than placebo at reducing liver fat as measured by MRI‐PDFF (mean difference between the ezetimibe and placebo arms ‐1.3%, P = 0.4). Compared to baseline, however, end‐of‐treatment MRI‐PDFF was significantly lower in the ezetimibe arm (15%‐11.6%, P < 0.016) but not in the placebo arm (18.5%‐16.4%, P = 0.15). There were no significant differences in histologic response rates, serum alanine aminotransferase and aspartate aminotransferase levels, or longitudinal changes in two‐dimensional and three‐dimensional magnetic resonance elastography‐derived liver stiffness between the ezetimibe and placebo arms. Compared to histologic nonresponders (25/35), histologic responders (10/35) had a significantly greater reduction in MRI‐PDFF (‐4.35 ± 4.9% versus ‐0.30 ± 4.1%, P < 0.019). Conclusions : Ezetimibe did not significantly reduce liver fat in NASH. This trial demonstrates the application of colocalization of MRI‐PDFF‐derived fat maps and magnetic resonance elastography‐derived stiffness maps of the liver before and after treatment to noninvasively assess treatment response in NASH. (H epatology 2015;61:1239–1250)
A survey of clinician attitudes and self-reported practices regarding end-of-life care in heart failure
Foxen, Jilian L, Cole, Terese, Feely, Molly A., Loth, Ann R., Strand, Jacob J. , Wagner, Jean, Redfield, Margaret M. , Dunlay, Shannon M. , Wagner, Jean A, Swetz, Keith M.

Palliative Medicine | December 8, 2014 | Volume: 29 | Issue: 3 | Pages: 260-267

10.1177/0269216314556565 | PMID 25488909 Get It

Background: As heart failure often follows an unpredictable clinical trajectory, there has been an impetus to promote iterative patient-provider discussions regarding prognosis and preferences for end-of-life care. Aim: To examine clinicians’ practices, expectations, and personal level of confidence in discussing goals of care and providing end-of-life care to their patients with heart failure. Design: Multi-site clinician survey. Setting and Participants: Physicians, nurse practitioners, and physician assistants at Mayo Clinic (Rochester, Minnesota, USA) and its surrounding health system were asked to participate in an electronic survey in October 2013. Tertiary Care Cardiology, Community Cardiology, and Primary Care clinicians were surveyed. Results: A total of 95 clinicians participated (52.5% response rate). Only 12% of clinicians reported having annual end-of-life discussions as advocated by the American Heart Association. In total, 52% of clinicians hesitated to discuss end-of-life care citing provider discomfort (11%), perception of patient (21%) or family (12%) unreadiness, fear of destroying hope (9%), or lack of time (8%). Tertiary and Community Cardiology clinicians (66%) attributed responsibility for end-of-life discussions to the heart failure cardiologist, while 66% of Primary Care clinicians felt it was their responsibility. Overall, 30% of clinicians reported a low or very low level of confidence in one or more of the following: initiating prognosis or end-of-life discussions, enrolling patients in hospice, or providing end-of-life care. Most clinicians expressed interest in further skills acquisition. Conclusion: Clinicians vary in their views and approaches to end-of-life discussions and care. Some lack confidence and most are interested in further skills acquisition.
Therapeutic Hypothermia and Targeted Temperature Management After Cardiac Arrest
Freeman, William D. , Karnatovskaia, Lioudmila V. , Vadeboncoeur, Tyler F. , Freeman, William D

JAMA Neurology | December 8, 2014 | Volume: 71 | Issue: 12 | Pages: 1577

10.1001/jamaneurol.2014.3125 | PMID 25486209 Get It

Disturbances of gastrointestinal transit and autonomic functions in postural orthostatic tachycardia syndrome
Loavenbruck, Adam , Iturrino, Johanna , Sletten, D. M., Low, P. A., Zinsmeister, Alan R., Bharucha, Adil E. , Singer, Wolfgang

Neurogastroenterology & Motility | December 8, 2014 | Volume: 27 | Issue: 1 | Pages: 92-98

10.1111/nmo.12480 | PMID 25483980 Get It

Abstract Background Gastrointestinal symptoms are common in the postural orthostatic tachycardia syndrome ( POTS ). However, few studies have evaluated gastrointestinal transit in POTS . Our primary objectives were to evaluate gastrointestinal emptying and the relationship with autonomic dysfunctions in POTS . Methods We reviewed the complete medical records of all patients aged 18 years and older with POTS diagnosed by a standardized autonomic reflex screen who also had a scintigraphic assessment of gastrointestinal transit at Mayo Clinic Rochester between 1998 and 2012. Associations between specific gastric emptying and autonomic (i.e., cardiovagal, adrenergic, and sudomotor) disturbances were evaluated. Key Results Among 163 patients (140 women, mean [± SEM ] age 30 [±1] years), 55 (34%) had normal, 30 (18%) had delayed, and 78 (48%) had rapid gastric emptying. Fifty‐eight patients (36%) had clinical features of physical deconditioning, which was associated ( p = 0.02) with rapid gastric emptying. Associations with delayed gastric emptying included vomiting, which was more common ( p < 0.003), and anxiety or depression, which was less common ( p = 0.02). The tilt‐associated increase in heart rate and reduction in systolic BP at 1 min was associated ( p < 0.05), being greater in patients with delayed gastric emptying. Conclusions & Inferences Two‐thirds of patients with POTS and GI symptoms had abnormal, most frequently rapid gastric emptying. Except for more severe adrenergic impairment in patients with delayed gastric emptying, the pattern of autonomic dysfunction did not discriminate among gastric emptying groups. Further studies are necessary to ascertain whether extravascular volume depletion and/or deconditioning contribute to POTS in patients with gastrointestinal symptoms.
Building Partnerships Through International Nursing Initiatives
Twedell, Diane M.

The Journal of Continuing Education in Nursing | December 8, 2014 | Volume: 37 | Issue: 1 | Pages: 15-15

10.3928/00220124-20060101-05 Get It

Pearls & Oy-sters: HyperCKemia with limb-girdle weakness
Ghosh, Partha S. , Lahoria, Rajat , Milone, Margherita , Sorenson, Eric J.

Neurology | December 8, 2014 | Volume: 83 | Issue: 24 | Pages: No page available

10.1212/wnl.0000000000001071 | PMID 25488998 Get It

NMDA receptor encephalitis causing reversible caudate changes on MRI and PET imaging
Lowe, Val J. , Robertson, Carrie E. , Pittock, Sean J. , Tobin, William O, Strand, Edythe A. , Tobin, W. Oliver , Clark, Heather M. , Pittock, S J , Robertson, Carrie E

Neurology Clinical Practice | December 8, 2014 | Volume: 4 | Issue: 6 | Pages: 470-473

10.1212/cpj.0000000000000074 | PMID 25566417 Get It

MRI spot sign
Cutsforth‐Gregory, Jeremy K. , Black, David F. , Hoffman, E. Matthew , Datar, Sudhir , Datar, Sudhir V, Wijdicks, Eelco F., Wijdicks, Eelco F. M.

Neurology Clinical Practice | December 8, 2014 | Volume: 4 | Issue: 6 | Pages: 528-529

10.1212/cpj.0000000000000064 | PMID 29451538 Get It